GlassScriptPhysician profile
Denia Caneta
NPI 1558922328
$11,504.52
in general payments reported to CMS, 2019-2025
65 companies · $2,901 in 2025
The $2,901 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $870 · 2022: $1,827 · 2023: $2,247 · 2024: $3,660 · 2025: $2,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,550 · Education: $933 · Travel and Lodging: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,549.54 |
| Education | $933.19 |
| Travel and Lodging | $324.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,131.47 | 2021-2023 | Interstim |
| Astrazeneca Pharmaceuticals LP | $908.30 | 2021-2025 | Lynparza, Enhertu, Tagrisso |
| Astellas Pharma US INC | $787.35 | 2021-2025 | Xospata, Xtandi, Myrbetriq |
| Abbvie INC. | $770.19 | 2022-2025 | |
| Incyte Corporation | $456.15 | 2024-2025 | Monjuvi, Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $421.16 | 2021-2025 | |
| Daiichi Sankyo INC. | $414.34 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Urovant Sciences INC | $387.22 | 2022 | |
| Gilead Sciences, INC. | $373.87 | 2024-2025 | Trodelvy |
| Lilly USA, LLC | $363.15 | 2024-2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $304.80 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $304.14 | 2021-2025 | Cabometyx |
| Sumitomo Pharma America, INC. | $296.40 | 2023 | Gemtesa, Orgovyx |
| Pfizer INC. | $290.43 | 2021-2024 | |
| Sobi, INC | $288.27 | 2024-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $271.28 | 2023-2025 | Erleada, Rybrevant, Tecvayli |
| Ultragenyx Pharmaceutical INC. | $239.91 | 2022-2023 | |
| Tempus Ai, INC | $221.71 | 2025 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $219.74 | 2021-2025 | |
| Eisai INC. | $197.44 | 2024 | |
| Merck Sharp & Dohme LLC | $168.57 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $168.56 | 2024 | Iclusig, Fruzaqla, Ninlaro |
| Halozyme INC | $167.52 | 2023 | |
| Antares Pharma, INC. | $164.39 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Genzyme Corporation | $161.85 | 2025 | |
| Genentech USA, INC. | $143.92 | 2024-2025 | Polivy, Phesgo, Itovebi |
| Dendreon Pharmaceuticals LLC | $136.18 | 2021-2023 | Provenge |
| Madrigal Pharmaceuticals | $135.99 | 2025 | Rezdiffra |
| Horizon Therapeutics Plc | $124.98 | 2023 | Krystexxa |
| Ipsen Biopharmaceuticals, INC | $124.84 | 2024-2025 | Onivyde, Iqirvo |
| Celgene Corporation | $103.47 | 2021-2025 | Reblozyl |
| Btg International INC. | $96.40 | 2021 | |
| Pharmacosmos Therapeutics INC. | $82.92 | 2024 | Monoferric |
| Scynexis, INC. | $76.65 | 2022 | |
| Pharmaessentia USA Corporation | $69.08 | 2024-2025 | Besremi |
| Accord Healthcare, INC. | $67.23 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $64.75 | 2024-2025 | Dupixent |
| Servier Pharmaceuticals LLC | $55.27 | 2025 | |
| Puma Biotechnology, INC. | $54.81 | 2024 | |
| Olympus America INC. | $50.35 | 2022-2023 | Itind System |
| Jazz Pharmaceuticals INC. | $47.63 | 2025 | |
| Octapharma USA, INC. | $45.45 | 2025 | Octagam Immune Globulin (Human) |
| Array Biopharma INC | $40.07 | 2025 | Lorbrena, Braftovi, Mektovi |
| Stemline Therapeutics INC. | $37.13 | 2025 | Orserdu |
| Springworks Therapeutics, INC. | $35.31 | 2025 | Ogsiveo |
| Tersera Therapeutics LLC | $32.60 | 2025 | Xermelo |
| Myriad Genetic Laboratories, INC. | $32.24 | 2024 | Mychoice Cdx |
| Kowa Pharmaceuticals America, INC. | $31.34 | 2022 | |
| Agios Pharmaceuticals, INC. | $28.13 | 2025 | Pyrukynd |
| Progenics Pharmaceuticals, INC. | $27.73 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.94 | 2025 | Reblozyl |
| Biocon Biologics INC | $23.16 | 2024 | Ogivri |
| Deciphera Pharmaceuticals INC. | $22.89 | 2025 | Qinlock, Romvimza |
| Sun Pharmaceutical Industries INC. | $22.28 | 2023 | Yonsa |
| Recordati_rare_diseases_inc. | $21.55 | 2024 | Sylvant |
| 180 Medical, INC. | $20.70 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $20.13 | 2022 | |
| Novocure INC. | $18.78 | 2025 | Optune Lua (Novottf-200t) |
| Kite Pharma, INC. | $17.87 | 2024 | Yescarta |
| Tolmar, INC. | $17.84 | 2023 | |
| Myovant Sciences INC. | $16.99 | 2021 | |
| Coloplast Corp | $14.64 | 2023 | Speedicath |
| Beone Medicines USA, INC. | $14.34 | 2025 | Brukinsa |
| Teleflex LLC | $14.08 | 2021 | |
| Iovance Biotherapeutics, INC. | $10.65 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denia Caneta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.